Protecting intubated patients from the threat of antimicrobial resistant infections with monoclonal antibodies.
作者信息
Baker Stephen, Kellam Paul, Krishna Aishwarya, Reece Stephen
机构信息
Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK.
Kymab, Babraham Research Campus, Cambridge CB22 3AT, UK.
出版信息
Lancet Microbe. 2020 Sep;1(5):e191-e192. doi: 10.1016/S2666-5247(20)30126-9. Epub 2020 Sep 7.
Abstract
摘要
相似文献
1
Protecting intubated patients from the threat of antimicrobial resistant infections with monoclonal antibodies.
Lancet Microbe. 2020 Sep;1(5):e191-e192. doi: 10.1016/S2666-5247(20)30126-9. Epub 2020 Sep 7.
2
Monoclonal antibodies as antibacterial therapies: thinking outside of the box.
Lancet Infect Dis. 2021 Sep;21(9):1201-1202. doi: 10.1016/S1473-3099(21)00062-1. Epub 2021 Apr 21.
3
Where are we with monoclonal antibodies for multidrug-resistant infections?
Drug Discov Today. 2019 May;24(5):1132-1138. doi: 10.1016/j.drudis.2019.03.002. Epub 2019 Mar 8.
4
Multidrug-Resistant Corynebacterium striatum Associated with Increased Use of Parenteral Antimicrobial Drugs.
Emerg Infect Dis. 2016 Nov;22(11):1908-14. doi: 10.3201/eid2211.160141.
5
Editorial: Enterobacteriaceae Antimicrobial Agents and Resistance: Relationship With the Therapeutic Approach.
Front Cell Infect Microbiol. 2021 Sep 14;11:728371. doi: 10.3389/fcimb.2021.728371. eCollection 2021.
6
Shigella Antimicrobial Drug Resistance Mechanisms, 2004-2014.
Emerg Infect Dis. 2016 Jun;22(6):1083-5. doi: 10.3201/eid2206.152088.
7
Anti-infective monoclonal antibodies: perils and promise of development.
Nat Rev Drug Discov. 2006 Mar;5(3):191-5. doi: 10.1038/nrd1987.
8
Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: the state of the art.
Arch Immunol Ther Exp (Warsz). 2006 Mar-Apr;54(2):113-20. doi: 10.1007/s00005-006-0012-4. Epub 2006 Mar 24.
9
Protecting against future shock--inhalational anthrax.
N Engl J Med. 2009 Jul 9;361(2):191-3. doi: 10.1056/NEJMe0903259.
10
[Advances in the research of treating multi-drug resistant bacterial infections].
Zhonghua Shao Shang Za Zhi. 2016 Sep 20;32(9):539-41. doi: 10.3760/cma.j.issn.1009-2587.2016.09.006.
引用本文的文献
1
Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii.
Nat Commun. 2024 Sep 12;15(1):7979. doi: 10.1038/s41467-024-52357-8.
2
Healthcare as a driver, reservoir and amplifier of antimicrobial resistance: opportunities for interventions.
Nat Rev Microbiol. 2024 Oct;22(10):636-649. doi: 10.1038/s41579-024-01076-4. Epub 2024 Jul 24.
3
Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague.
Antibodies (Basel). 2023 May 8;12(2):33. doi: 10.3390/antib12020033.
4
Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection.
mBio. 2022 Feb 22;13(1):e0351721. doi: 10.1128/mbio.03517-21. Epub 2022 Jan 11.
本文引用的文献
1
The global preclinical antibacterial pipeline.
Nat Rev Microbiol. 2020 May;18(5):275-285. doi: 10.1038/s41579-019-0288-0. Epub 2019 Nov 19.
2
Vaccine Evolution and Its Application to Fight Modern Threats.
Front Immunol. 2019 Jul 25;10:1722. doi: 10.3389/fimmu.2019.01722. eCollection 2019.
3
Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study.
J Infect. 2019 Aug;79(2):130-138. doi: 10.1016/j.jinf.2019.05.017. Epub 2019 May 28.
4
Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top.
Front Immunol. 2018 May 30;9:1068. doi: 10.3389/fimmu.2018.01068. eCollection 2018.
5
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.
Zotero 插件